89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

Summary

89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.

Conditions

• Clear Cell Renal Cell Carcinoma

Interventions

DIAGNOSTIC_TEST

89Zr-girentuximab

Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.

Sponsors & Collaborators

• Telix Pharmaceuticals (Innovations) Pty Limited

  lead INDUSTRY

Principal Investigators

• Howard Gurney, MD · Macquarie University Hospital

• Francoise Brodere, MD · University Hospital ICO, Nantes, France

• Peter Mulders, MD · Radboud University Medical Center

• Marcel Stokkel, MD · The Netherlands Cancer Institute

• Declan Murphy, MD · Victorian Comprehensive Cancer Centre

• Andrew Scott, MD · Olivia Newton John Cancer Research Center, Austin Hospital

• Simon Wood, MD · Princess Alexander Hospital

• Mark Frydenberg, MD · Cabrini Hospital

• David Chan · Royal North Shore Hospital

• Jean-Christophe Bernhard, MD · CHU de Bordeaux, Groupe Hospitalier Pellegrin

• Pierre Olivier, MD · CHRU de Nancy - Hôpitaux de Brabois

• Linda Heijmen, MD · Leiden University Medical Centre

• Martin Geert Steffens, MD · Isala

• Karolien Goffin, MD · Universitair Ziekenhuis Leuven

• Carlos Artigas Guix, MD · Instutit Jules Bordet

• Nicolas Lumen, MD · University Ghent

• Sumer Baltaci, MD · Ankara University

• Bulent Akdogan, MD · Ankara Hacettepe University

• Bulent Onal, MD · Istanbul University - Cerrahpasa

• Tamer Aksoy, MD · Istanbul Training and Research Hospital

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-08-15

Primary Completion

2022-10-20

Completion

2022-11-07

FDA Drug

Yes

Countries

• United States
• Australia
• Belgium
• Canada
• France
• Netherlands
• Turkey (Türkiye)
• United Kingdom

Study Locations